- Home
- CANF vs PHGE Comparison
CANF vs PHGE Comparison
Compare CANF & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- PHGE
- Stock Information
- Founded
- CANF 1994
- PHGE 2015
- Country
- CANF Israel
- PHGE Israel
- Employees
- CANF N/A
- PHGE N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- CANF Health Care
- PHGE Health Care
- Exchange
- CANF Nasdaq
- PHGE Nasdaq
- Market Cap
- CANF 14.8M
- PHGE 14.6M
- IPO Year
- CANF N/A
- PHGE N/A
- Fundamental
- Price
- CANF $1.04
- PHGE $0.56
- Analyst Decision
- CANF Strong Buy
- PHGE Strong Buy
- Analyst Count
- CANF 2
- PHGE 2
- Target Price
- CANF $14.00
- PHGE $23.00
- AVG Volume (30 Days)
- CANF 172.6K
- PHGE 59.0K
- Earning Date
- CANF 05-27-2025
- PHGE 05-15-2025
- Dividend Yield
- CANF N/A
- PHGE N/A
- EPS Growth
- CANF N/A
- PHGE N/A
- EPS
- CANF N/A
- PHGE N/A
- Revenue
- CANF $674,000.00
- PHGE N/A
- Revenue This Year
- CANF $461.72
- PHGE N/A
- Revenue Next Year
- CANF N/A
- PHGE N/A
- P/E Ratio
- CANF N/A
- PHGE N/A
- Revenue Growth
- CANF N/A
- PHGE N/A
- 52 Week Low
- CANF $1.02
- PHGE $0.48
- 52 Week High
- CANF $4.69
- PHGE $4.99
- Technical
- Relative Strength Index (RSI)
- CANF 37.30
- PHGE 47.20
- Support Level
- CANF $0.98
- PHGE $0.50
- Resistance Level
- CANF $1.14
- PHGE $0.59
- Average True Range (ATR)
- CANF 0.06
- PHGE 0.04
- MACD
- CANF 0.01
- PHGE -0.00
- Stochastic Oscillator
- CANF 32.59
- PHGE 42.73
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).